DVAX Live signals | Maximize Profits with Getagraph.com

SELL 100942 min ago

@ $12.42

Issued: 14 Feb 2024 @ 09:30

Return: -7.53%

Previous signal: Feb 12 - 15:56

Previous signal: Buy

Return: -2.97 %

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 12:52):

Stats
Today's Volume	289 847
Average Volume	1.96M
Market Cap	1.50B
EPS	$0 ( 2024-02-22 )
Next earnings date	( $-0.0500 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-229.70
ATR14	$0.00500 (0.04%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-29	Slebir John L	Sell	0	Common Stock
2024-03-29	Slebir John L	Sell	300 000	Stock Option (Right to Buy)
2024-03-29	Slebir John L	Sell	80 000	Stock Options (Right to Buy)
2024-03-29	Slebir John L	Sell	50 000	Restricted Stock Unit
2024-03-29	Slebir John L	Sell	88 000	Stock Options (Right to Buy)

INSIDER POWER
-33.94
Last 100 transactions
Buy: 1 153 769 \| Sell: 2 721 592

Volume Correlation

Long: 0.06 (neutral)

Short: 0.41 (neutral)

Signal:(41.197) Neutral

Dynavax Technologies Corp Correlation

10 Most Positive Correlations
RMRM	0.942
SUSL	0.937
FNILX	0.937
PABU	0.935
MOR	0.934
CATH	0.933
BUFF	0.932
CACG	0.932
VONE	0.929
USXF	0.927

10 Most Negative Correlations
SDVY	-0.926
VC	-0.925
SMH	-0.923
OSIS	-0.923
HLNE	-0.922
NYMTM	-0.92
PSCI	-0.919
RNSC	-0.919
RNMC	-0.918
TER	-0.917

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Dynavax Technologies Corp Correlation - Currency/Commodity

0.61
( weak )

0.64
( weak )

0.00
( neutral )

0.62
( weak )

-0.71
( moderate negative )

Dynavax Technologies Corp Financials

Annual	2023
Revenue:	$232.28M
Gross Profit:	$182.12M (78.40 %)
EPS:	$-0.0496

Q4	2023
Revenue:	$55.60M
Gross Profit:	$46.91M (84.37 %)
EPS:	$0.00170

Q3	2023
Revenue:	$69.51M
Gross Profit:	$56.29M (80.97 %)
EPS:	$0.110

Q2	2023
Revenue:	$60.25M
Gross Profit:	$46.71M (77.53 %)
EPS:	$0.0267

Financial Reports:

No articles found.

Dynavax Technologies Corp

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.